Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | neuroendocrine convertase 2 | 0.0045 | 0.1833 | 0.0526 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0043 | 0.1672 | 0.5 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0043 | 0.1672 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.012 | 1 | 1 |
Brugia malayi | celfurPC protein | 0.0058 | 0.3215 | 0.1693 |
Brugia malayi | endoprotease bli-4 precursor | 0.0071 | 0.4716 | 0.353 |
Echinococcus granulosus | furin | 0.0071 | 0.4716 | 1 |
Schistosoma mansoni | subfamily S8B unassigned peptidase (S08 family) | 0.0071 | 0.4716 | 1 |
Loa Loa (eye worm) | endoprotease bli-4 | 0.0071 | 0.4716 | 0.4716 |
Echinococcus multilocularis | 0.0058 | 0.3215 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.4716 | 0.4716 |
Brugia malayi | sulfakinin receptor protein | 0.012 | 1 | 1 |
Echinococcus multilocularis | neuroendocrine convertase 2 | 0.0045 | 0.1833 | 0.1038 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Activation of SMN expressed in HEK293 cells assessed as concentration required to reach 50% of maximum luciferase signal by SMN2-promotor driven luciferase reporter gene assay | ChEMBL. | 21819082 | |
Potency (functional) | 30.7483 uM | PUBCHEM_BIOASSAY: Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Modulation of SMN1 Expression for Further Probe SAR. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1474] | ChEMBL. | No reference |
Potency (functional) | 112.957 uM | PUBCHEM_BIOASSAY: Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Interaction with Luciferase Reporter for Further Probe SAR. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1474] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.